West Pharmaceutical Services (NYSE:WST) Shares Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of West Pharmaceutical Services, Inc. (NYSE:WST). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in West Pharmaceutical Services stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

West Pharmaceutical Services Stock Down 1.8 %

Shares of West Pharmaceutical Services stock opened at $222.08 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23. The firm’s 50-day moving average is $263.98 and its two-hundred day moving average is $297.88. West Pharmaceutical Services, Inc. has a 1 year low of $197.01 and a 1 year high of $396.75. The stock has a market cap of $16.06 billion, a price-to-earnings ratio of 33.20, a PEG ratio of 6.74 and a beta of 1.09.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, topping the consensus estimate of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The firm had revenue of $748.80 million during the quarter, compared to analyst estimates of $739.59 million. As a group, research analysts expect that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 7th. Shareholders of record on Wednesday, April 30th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, April 30th. This represents a $0.84 dividend on an annualized basis and a yield of 0.38%. West Pharmaceutical Services’s dividend payout ratio is currently 12.56%.

Institutional Investors Weigh In On West Pharmaceutical Services

Several institutional investors and hedge funds have recently modified their holdings of WST. Fiera Capital Corp raised its stake in shares of West Pharmaceutical Services by 13.2% in the fourth quarter. Fiera Capital Corp now owns 140,893 shares of the medical instruments supplier’s stock valued at $46,151,000 after acquiring an additional 16,418 shares in the last quarter. Trust Point Inc. grew its position in shares of West Pharmaceutical Services by 321.0% in the 4th quarter. Trust Point Inc. now owns 3,183 shares of the medical instruments supplier’s stock valued at $1,043,000 after buying an additional 2,427 shares during the last quarter. Savant Capital LLC raised its stake in West Pharmaceutical Services by 15.0% during the 4th quarter. Savant Capital LLC now owns 1,003 shares of the medical instruments supplier’s stock worth $329,000 after acquiring an additional 131 shares in the last quarter. Nomura Asset Management Co. Ltd. increased its position in West Pharmaceutical Services by 22.4% during the third quarter. Nomura Asset Management Co. Ltd. now owns 130,345 shares of the medical instruments supplier’s stock worth $39,124,000 after buying an additional 23,850 shares during the period. Finally, Swedbank AB raised its position in West Pharmaceutical Services by 44.6% in the 3rd quarter. Swedbank AB now owns 7,195 shares of the medical instruments supplier’s stock valued at $2,160,000 after purchasing an additional 2,220 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

WST has been the topic of several research analyst reports. Evercore ISI began coverage on shares of West Pharmaceutical Services in a research report on Tuesday, March 18th. They set an “outperform” rating and a $275.00 target price on the stock. KeyCorp decreased their price objective on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price target for the company in a research note on Friday, February 14th. StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Thursday, February 27th. Finally, Wolfe Research began coverage on West Pharmaceutical Services in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $332.50.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.